靶向淋巴瘤细胞共价沉积的补体C3片段增强CD20单克隆抗体治疗
研究提出靶向瘤细胞表面共价沉积的补体C3d可清除CD20阴性残留肿瘤细胞。作者构建抗人/鼠C3d嵌合抗体C8xi及兔源抗C3d抗体,在患者来源异种移植模型和3种非霍奇金淋巴瘤模型中,抗C3d抗体联合奥法木单抗或利妥昔单抗延长了小鼠生存。
要点
- 奥法木单抗治疗后CLL循环肿瘤细胞在24小时内丢失CD20并被C3d调理。
- 抗C3d抗体C8xi在患者来源异种移植模型中有效清除CD20阴性C3d阳性CLL细胞。
- 抗C3d兔/人嵌合IgG1联合CD20单抗延长3种NHL模型小鼠生存。
核心结论
- 作者提出抗C3d单抗联合补体固定型CD20单抗可克服抗原丢失逃逸并提高单抗治疗疗效。
研究设计与样本
- 研究构建了抗人C3d的小鼠/人嵌合IgG1 C8xi及兔源抗C3d单抗,并在患者来源异种移植模型和3种非霍奇金淋巴瘤小鼠模型中验证。
主要发现
- 慢性淋巴细胞白血病患者接受奥法木单抗后24小时内循环肿瘤细胞丢失CD20并被C3d调理。
- C8xi在患者来源异种移植模型中对CD20阴性、C3d调理的CLL细胞有效。
- 在弥漫大B细胞淋巴瘤模型SU-DHL-6中,单药CD20单抗中位生存114天,联合治疗未达到中位生存(P = .008)。
- 在另一NHL模型SU-DHL-4中,单药和联合抗体治疗均清除了大多数小鼠的淋巴瘤。
- 两个队列的长期生存小鼠均未见不良效应证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal antibodies (mAbs) improve survival of patients with mature B-cell malignancies. Fcγ receptor-dependent effector mechanisms kill tumor cells but can promote antigen loss through trogocytosis, contributing to treatment failures. Cell-bound mAbs trigger the complement cascade to deposit C3 activation fragments and lyse cells. Within 24 hours after ofatumumab administration to patients with chronic lymphocytic leukemia (CLL), circulating tumor cells had lost CD20 and were opsonized with C3d, the terminal covalently bound form of complement protein C3. We hypothesized that C3d provides a target to eliminate residual CD20- tumor cells. To test this hypothesis, we generated C8xi, a mouse/human chimeric immunoglobulin G1 (IgG1) that reacts with human but not mouse C3d. C8xi was effective in a patient-derived xenograft model against CD20-, C3d opsonized CLL cells from patients treated with ofatumumab. We also generated rabbit mAbs, 2 of which were chosen because they bound mouse and human C3d with low nanomolar affinity but were minimally cross-reactive with full-length C3. Anti-C3d rabbit/human chimeric IgG1 in combination with ofatumumab or rituximab prolonged survival of xenografted mice that model 3 different types of non-Hodgkin lymphoma (NHL). For example, in a diffuse large B-cell lymphoma model (SU-DHL-6), median survival with single-agent CD20 mAb was 114 days but was not reached for mAb combination treatment (P = .008). In another NHL model (SU-DHL-4), single-agent and combination mAb therapy eradicated lymphoma in most mice. In long-term survivors from both cohorts, there was no evidence of adverse effects. We propose that C3d mAbs combined with complement-fixing CD20 mAbs can overcome antigen-loss escape and increase efficacy of mAb-based therapy.
引用
- Baskar S, Peng H, Gaglione EM, et al. Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells. Blood. 2025. PMID: 39774793. doi:10.1182/blood.2024024846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。